Phaseline

Targets › HNMT

HNMT (Histamine N-methyltransferase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jan 2027.

Inactivates histamine by N-methylation. Plays an important role in degrading histamine and in regulating the airway response to histamine. (UniProt, P50135)

Open in Phaseline: the race on HNMT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Center for Vulvovaginal DisordersKetotifen Fumarate 0.25% Cream
Mast-cell stabilizer and histamine H1 antagonist
HNMTPhase 2Provoked VestibulodyniaJan 2027

Conditions

Provoked Vestibulodynia (1)

Modalities

small molecule (1)

Companies

Center for Vulvovaginal Disorders (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.